drugset / Trial / NCT07709910

A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

NCT07709910

Phase 3 Not yet recruiting 382 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.

Timeline

Start
2026-07
Primary completion
2028-11
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject KAI-9531 Unknown

Indications

No indication recorded.